A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate

@inproceedings{Smolen2017ARP,
  title={A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate},
  author={Josef S Smolen and Sandeep K Agarwal and Elena I Ilivanova and Xie Lillian Xu and Ye Miao and Yanli Zhuang and Ivo P. Nnane and Waldemar Radziszewski and Andrew J. Greenspan and Anna M Beutler and Daniel G. Baker},
  booktitle={Annals of the rheumatic diseases},
  year={2017}
}
OBJECTIVE Interleukin (IL)-12 and IL-23 have been implicated in the pathogenesis of rheumatoid arthritis (RA). The safety and efficacy of ustekinumab, a human monoclonal anti-IL-12/23 p40 antibody, and guselkumab, a human monoclonal anti-IL-23 antibody, were evaluated in adults with active RA despite methotrexate (MTX) therapy. METHODS Patients were randomly assigned (1:1:1:1:1) to receive placebo at weeks 0, 4 and every 8 weeks (n=55), ustekinumab 90 mg at weeks 0, 4 and every 8 weeks (n=55… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 14 times over the past 90 days. VIEW TWEETS

From This Paper

Figures, tables, results, connections, and topics extracted from this paper.
14 Extracted Citations
51 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 14 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 51 references

Similar Papers

Loading similar papers…